Pharma companies directory 2026

    Pharmaceutical Companies in Ethiopia

    Ethiopia is trying to turn the continent’s second-largest population into a manufacturing story: Kilinto’s dedicated pharmaceutical park on the edge of Addis Ababa, an EFDA that has reached WHO Maturity Level 3, and a state buyer, EPSS, that still decides most of what reaches public wards.

    The story is unfinished. Foreign exchange for APIs and packing materials has been scarce for years, so plants that look modern on a Kilinto tour have often run at a fraction of installed capacity. Officials now say local factories cover more than two fifths of medicine supply and about 44 percent of national procurement — a jump from the high-single-digit shares quoted earlier in the decade — but finished-dose imports and EPSS international tenders still fill the gaps that idle lines cannot. EPHARM and Addis Pharmaceutical Factory are the older Ethiopian names; Cadila’s joint venture, Humanwell, Julphar, Sino-Ethiop Associate, Sansheng, Kilitch Estro and Glocare are the foreign-backed plants that were invited in to substitute imports. Novartis is present mainly through access portfolios rather than a full originator campus; GSK’s visible role has been vaccines and historical commercial supply, not a Kilinto factory. AU and IGAD conversations treat Addis as a possible regional source once EFDA’s maturity level and EPSS contracts become predictable. Market-size figures wander between about $1.3 billion and $1.8 billion depending on whether devices and public grants are counted, so this page stays with institutions and named plants. The list is the set of manufacturers, foreign ventures, the regulator and the pooled buyer a launch or localisation brief has to name before anyone talks about Hawassa or Dire Dawa demand.

    Updated September 2026 · Ethiopian Food and Drug Authority (EFDA) — registered medicines and licensed manufacturers as of September 2026 · 18 named accounts

    Request a proposal for EthiopiaBrowse the 18 companies

    $1.3–1.8bn

    Published range for Ethiopia’s pharmaceutical market (Manufacturing Africa 2022; Ethiopian Pharmaceutical Association, later)

    >40%

    Local production share of medicine supply cited by EFDA / World Bank feature, May 2026

    ~44%

    Domestic suppliers’ share of national procurement, Ministry of Health, May 2026 (from about 8% five to six years earlier)

    ML3

    EFDA WHO Maturity Level 3 for medicines regulation — ninth in Africa, first in IGAD

    Named accounts

    Top pharmaceutical companies in Ethiopia

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Ethiopian Food and Drug Authority (EFDA) — registered medicines and licensed manufacturers (as of 2026-09-04).
    #CompanyHQ
    01Ethiopian Pharmaceuticals Manufacturing (EPHARM)Addis Ababa
    02Addis Pharmaceutical FactoryAddis Ababa
    03Cadila Pharmaceuticals EthiopiaAddis Ababa
    04Humanwell Pharmaceutical EthiopiaKilinto, Addis Ababa
    05Julphar EthiopiaAddis Ababa
    06Sino-Ethiop AssociateAddis Ababa
    07Sansheng Pharmaceuticals EthiopiaAddis Ababa
    08Kilitch Estro BiotechKilinto, Addis Ababa
    09Glocare Pharma ManufacturingKilinto, Addis Ababa
    10East African PharmaceuticalsAddis Ababa
    11Pharmacure PLCAddis Ababa
    12Trust PharmaceuticalsAddis Ababa
    13Africure Pharmaceuticals ManufacturingKilinto, Addis Ababa
    14NovartisAccess programmes / Addis Ababa
    15GSKVaccines and historical commercial / Addis Ababa
    16Ethiopian Food and Drug Authority (EFDA)Addis Ababa
    17Ethiopian Pharmaceutical Supply Service (EPSS)Addis Ababa
    18Kilinto Pharmaceutical Special Economic ZoneAddis Ababa

    Primary research

    These are the pharmaceutical companies accounts we study in Ethiopia

    Need account-level or SKU-level data for a brand in Ethiopia? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

    Planning research in Ethiopia?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top market research companies in Ethiopia (2026)

    How the market is structured

    How EFDA files and EPSS contracts decide what Ethiopians actually receive

    A medicine may be sold only after the Ethiopian Food and Drug Authority issues a marketing authorisation and, for a local plant, a facility-level GMP certificate. Since mid-2024 that GMP bar has applied to every domestic factory, and in 2026 the Authority opened a contract-manufacturing route so idle Kilinto and Addis lines can legally make another company’s pack. Physical demand is dominated by the Ethiopian Pharmaceutical Supply Service, the pooled buyer that replaced PFSA: EPSS tenders for federal hospitals, regional health bureaus and many woredas, and a lost EPSS lot is a lost year for a plant that cannot freely sell the same batch into a thin private pharmacy trade. Private retail exists in Addis Ababa and in corridor towns, but household cash and forex-starved importers make it a poor substitute for a state contract. Foreign exchange is the hidden channel. Plants wait for dollars to buy APIs; importers wait for the same dollars to open letters of credit; EPSS itself has delayed awards when hard currency was missing. Kilinto — roughly 279 hectares with dedicated power and effluent treatment — was built to break that loop by clustering formulation, packaging and eventually some inputs. Hawassa’s industrial labour pool and Dire Dawa’s rail and dry-port role matter for distribution more than for plants today. AU and IGAD supply talks sit on top of this domestic machinery: if EFDA stays at Maturity Level 3 and EPSS pays on time, Ethiopian packs become candidates for neighbouring tenders; if either slips, the country remains an import destination with a photogenic park.

    Local

    EPHARM, Addis Pharmaceutical Factory, East African Pharmaceuticals, Pharmacure and Trust — Ethiopian-owned plants that lived on EPSS essentials before Kilinto existed and still bid those lots.

    • Ethiopian Pharmaceuticals Manufacturing (EPHARM)
    • Addis Pharmaceutical Factory
    • East African Pharmaceuticals
    • Pharmacure PLC
    • Trust Pharmaceuticals

    Multinational

    Cadila, Humanwell, Sansheng, Kilitch, Glocare, plus Novartis and GSK as access-and-vaccine names rather than factory owners. Chinese and Indian capital, not Swiss or British campuses, built the new lines.

    • Cadila Pharmaceuticals Ethiopia
    • Humanwell Pharmaceutical Ethiopia
    • Sansheng Pharmaceuticals Ethiopia
    • Kilitch Estro Biotech
    • Glocare Pharma Manufacturing
    • Novartis
    • GSK

    Regional

    Julphar from the Gulf, Sino-Ethiop Associate, and Africure’s pan-African JV — groups that treat Ethiopia as a Horn and IGAD manufacturing node, not only a 120-million-person domestic market.

    • Julphar Ethiopia
    • Sino-Ethiop Associate
    • Africure Pharmaceuticals Manufacturing

    Distributors & importers

    EFDA as the maturity-level-3 gate, EPSS as the pooled buyer, Kilinto SEZ as the land-and-utilities counterpart, and forex desks at the banks as the unofficial fourth gate.

    • Ethiopian Food and Drug Authority (EFDA)
    • Ethiopian Pharmaceutical Supply Service (EPSS)
    • Kilinto Pharmaceutical Special Economic Zone

    What is moving

    What is moving the pharmaceutical market in Ethiopia

    Kilinto park and import-substitution incentives

    Serviced plots, tax holidays and official price preferences of up to half for eligible domestic packs are why Indian and Chinese principals accepted a forex-difficult market; occupancy is still partial, so the next wave of plots is itself a competitive signal.

    EFDA maturity and the contract-manufacturing opening

    Maturity Level 3 plus a 2026 rule that lets one licensed plant make another company’s medicine is meant to turn idle shifts into legal supply, which changes partner screening: a brand may now rent a Kilinto line instead of building one.

    EPSS preference for local packs — when the dollars arrive

    Ministry figures showing local suppliers above two fifths of procurement only hold if EPSS can pay and if plants can buy APIs. Forex remains the choke; a preference rule without dollars restocks the import tender.

    AU and IGAD as a second customer, not a slogan

    Addis hosts the African Union, and EFDA’s IGAD-first maturity badge is being used to argue that Ethiopian packs can move into neighbouring tenders. That export story is real only for plants that already satisfy EPSS quality and volume at home.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical companies in Ethiopia

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Ethiopia:
    • EPSS tender reconstructions by molecule: local versus imported winners, stated preference margins, and whether awarded packs were actually delivered after forex delays.
    • Kilinto and older Addis plant walks with quality and production heads on utilisation, API waits, and whether the 2026 contract-manufacturing rule is already being used.
    • Addis Ababa, Hawassa and Dire Dawa private-pharmacy availability checks on essential orals, to see what leaks out of EPSS into cash retail.
    • Access-versus-factory separation: interviews that keep Novartis Access and GSK vaccine supply out of the Kilinto capacity conversation so a client does not plan a plant tour that does not exist.

    Questions

    Frequently Asked Questions

    Which pharmaceutical companies manufacture inside Ethiopia?

    EPHARM and Addis Pharmaceutical Factory are the historic local names. Cadila, Humanwell, Julphar, Sino-Ethiop Associate, Sansheng, Kilitch Estro, Glocare and Africure are the foreign-backed factories, several of them on Kilinto. Novartis and GSK should not be counted as manufacturers here.

    What does EFDA Maturity Level 3 change for a foreign brand?

    It tells WHO and neighbouring regulators that Ethiopia’s medicines system meets a defined institutional standard. In practice it shortens some reliance conversations and is a prerequisite for treating an Ethiopian pack as an IGAD-credible source. It does not by itself speed a single dossier if the file is incomplete.

    Why do people say forex decides more than the tender?

    Plants cannot run without imported APIs, and importers cannot clear finished doses without letters of credit. EPSS can award a lot that nobody can manufacture or ship until dollars are allocated. That is why utilisation rates at otherwise modern factories have sat far below nameplate capacity.

    Is Kilinto a substitute for EPSS?

    No. Kilinto is land, power and permits. EPSS is demand. A full park with a late-paying or forex-blocked buyer still leaves pallets in the warehouse. The two institutions have to move together or the import-substitution numbers reverse.

    How does BioNixus take an Ethiopian pharmaceutical brief on the ground?

    We interview EPSS procurement officers and hospital pharmacists in Addis Ababa, walk Kilinto and older Addis plants with quality heads, test private-pharmacy availability in Hawassa and Dire Dawa, and separate access-programme volume (Novartis, vaccine partners) from factory volume.

    Is the Ethiopian company table ordered by turnover or plant size?

    Neither. This is a working account list, not a ranking. A name is here because it holds an EFDA licence, an EPSS award history, a Kilinto plot, or a documented access role. Installed capacity and last year’s EPSS share do not set the sequence.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Ethiopia. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Ethiopian Food and Drug Authority (EFDA) — registered medicines and licensed manufacturers, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Ethiopia, not size.

    • World Bank feature on EFDA Maturity Level 3 and local-production share, 26 May 2026
    • Ethiopian Ministry of Health / ENA interview on 44 percent local share of national procurement, 25 May 2026
    • Manufacturing Africa, Potential in local pharmaceutical manufacturing in Ethiopia (Kilinto 279 ha; 12 manufacturers; $1.3–1.7bn 2022 market)
    • Addis Fortune on EFDA contract-manufacturing directive, February 2026; AHRI local-manufacturer profiles, 2025
    • BioNixus Ethiopia plant, EPSS and pharmacy fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need brand and competitor data in Ethiopia?

    Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

    Planning research in Ethiopia?

    Primary research, market access & HEOR. Proposals within 48 hours.